source
- Fulcrum exploring a potential sale after FDA sidelined its sickle cell drugFulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.BioPharma Dive · 1mo ago↗ source
- What’s next for VEGF? #ASCO26 offered clues, but answers will have to waitCHICAGO — Not long ago, there were hopes that a new class of cancer drugs would repeat the success of Keytruda. Instead, it seems more likely they could end up making up for its weaknesses. Many ...Endpoints · 1mo ago↗ source
- STAT+: Radiopharmaceutical shows promise in post-Pluvicto settingAbivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The ReadoutSTAT